There are currently 980 clinical trials in Tampa, Florida looking for participants to engage in research studies. Trials are conducted at various facilities, including Moffitt Cancer Center, University of South Florida, H. Lee Moffitt Cancer Center and Research Institute and Tampa General Hospital. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
MElanoma Research Lymph Node Prediction Implementation National_001
Recruiting
MERLIN_001 is a prospective registry study of a primary melanoma gene-signature to predict sentinel node (SN) status and to determine its prognostic value for more accurate staging of SN-negative melanoma patients.
Gender:
All
Ages:
18 years and above
Trial Updated:
11/21/2023
Locations: Moffitt Cancer Center, Tampa, Florida
Conditions: Melanoma
Multi-Institutional Registry for Malignant Peripheral Nerve Sheath Tumors
Recruiting
First, the investigators plan to use a retrospective analysis to determine the clinical landscape of neurofibromatosis (NF)1-associated malignant peripheral nerve sheath tumor (MPNST) and precursor lesions (e.g., atypical or nodular plexiform neurofibromas). A worldwide database will be established, collecting, in a standardized manner, histologic, immunohistochemical, molecular, radiographic, treatment, and related clinical data from centers worldwide with expertise in these NF1-related cancers... Read More
Gender:
All
Ages:
All
Trial Updated:
11/20/2023
Locations: Moffitt Cancer Center, Tampa, Florida
Conditions: Malignant Peripheral Nerve Sheath Tumors
American Hepato-Pancreato-Biliary Association (AHPBA) Pancreatic Irreversible Electroporation (IRE) Registry
Recruiting
The purpose of this study is to create a registry to provide insight into treatment selection and treatment outcome of pancreatic IRE in order to develop an evidence base such that physicians can provide the best possible care to patients with pancreatic cancer requiring surgical interventions. The investigators seek a better understanding of the uses of ablation in the treatment of unresectable soft tissue pancreatic tumors and the limitations, concerns and complications that earlier users hav... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
11/16/2023
Locations: University of South Florida, Tampa, Florida
Conditions: Pancreatic Cancer
A Study of Telitacicept for the Treatment of Moderately to Severely Active Systemic Lupus Erythematosus (REMESLE-1)
Recruiting
The purpose of this study is to evaluate the efficacy and safety of telitacicept in the treatment of moderately to severely active SLE.
Gender:
All
Ages:
Between 12 years and 70 years
Trial Updated:
11/16/2023
Locations: Tampa, Florida Site, Tampa, Florida
Conditions: Systemic Lupus Erythematosus
Dose-escalation, Dose-expansion Study of Safety of PBCAR0191 in Patients With r/r NHL and r/r B-cell ALL
Recruiting
This is a Phase 1/2a, nonrandomized, open-label, parallel assignment, dose-escalation, and dose-optimization study to evaluate the safety and clinical activity of PBCAR0191 in adults with r/r B ALL (Cohort A) and in adults with r/r B-cell NHL (Cohort N) and identify a treatment regimen most likely to result in clinical efficacy while maintaining a favorable safety profile.
Gender:
All
Ages:
18 years and above
Trial Updated:
11/15/2023
Locations: H. Lee Moffitt Cancer Center, Tampa, Florida
Conditions: Non-Hodgkin Lymphoma, B-cell Acute Lymphoblastic Leukemia
Lenvatinib With Everolimus Versus Cabozantinib for Second-Line or Third-Line Treatment of Metastatic Renal Cell Cancer
Recruiting
This phase II trial compares the effects of lenvatinib given in combination with everolimus to the effects of cabozantinib given alone in treating patients with renal cell cancer (RCC) that has spread to other parts of the body (metastatic) and that got worse on a previous PD-1/PD-L1 checkpoint inhibitor. Lenvatinib, everolimus, and cabozantinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
Gender:
All
Ages:
18 years and above
Trial Updated:
11/13/2023
Locations: Moffitt Cancer Center, Tampa, Florida
Conditions: Advanced Clear Cell Renal Cell Carcinoma, Metastatic Clear Cell Renal Cell Carcinoma, Stage III Renal Cell Cancer AJCC v8, Stage IV Renal Cell Cancer AJCC v8
The KinematX Midcarpal Total Wrist Arthroplasty Registry
Recruiting
The goal of this observational study is to learn about functional and patient reported outcomes in patient undergoing total wrist replacement with the KinematX total wrist replacement study. The main questions it aims to answer are: What is the range of motion (flexion, extension, radial, ulnar, grip and pinch strength) at 3-, 6-, and 12-months after surgery and yearly up to 10 years among patients having total wrist replacement with the KinematX implant. What are the patient reported outcomes... Read More
Gender:
All
Ages:
Between 18 years and 85 years
Trial Updated:
11/13/2023
Locations: Florida Orthopaedic Institute, Tampa, Florida
Conditions: Scapholunate Advanced Collapse (SLAC), Scapholunate Crystalline Advanced Collapse (SCAC), Scaphoid, Trapezium, and Trapezoid Advanced Collapse (STTAC), Carpal Tunnel Syndrome (CTS), Kienbock's Disease of Adults, Radial Malunion, Ulnar Translocation, Post Traumatic Arthritis, Inflammatory Arthritis, Osteoarthritis, Scaphoid Non-union Advanced Collapse (SNAC)
Automated Imaging Differentiation of Parkinsonism
Recruiting
The purpose of this study is to test the performance of the AID-P across 21 sites in the Parkinson Study Group. Each site will perform imaging, clinical scales, diagnosis, and will upload the data to the web-based software tool. The clinical diagnosis will be blinded to the diagnostic algorithm and the imaging diagnosis will be compared to the movement disorders trained neurologist diagnosis.
Gender:
All
Ages:
Between 40 years and 80 years
Trial Updated:
11/13/2023
Locations: University of South Florida, Tampa, Florida
Conditions: Parkinson Disease, Multiple System Atrophy, Parkinson Variant, Progressive Supranuclear Palsy
BBD Longitudinal Study of Osteogenesis Imperfecta
Recruiting
Osteogenesis Imperfecta (OI) is a rare disorder of increased bone fragility characterized by fractures with minimal or absent trauma, dentinogenesis imperfecta (DI), and, in adult years, hearing loss. It is seen in both genders and all races. The clinical features of OI represent a continuum varying from perinatal lethality to individuals with severe skeletal deformities, mobility impairments, and very short stature to nearly asymptomatic individuals with a mild predisposition to fractures, norm... Read More
Gender:
All
Ages:
All
Trial Updated:
11/09/2023
Locations: University of South Florida, Tampa, Florida
Conditions: Osteogenesis Imperfecta
Monitoring Symptoms to Help Young Women Take Hormone Therapy for Stage I-III Breast Cancer, ASPEN Study
Recruiting
This phase III trial compares the effect of active symptom monitoring and patient education to patient education alone in helping young women with stage I-III breast cancer stay on their hormone therapy medicines. The patient education tool contains interactive weblinks which provide patients with education material about breast cancer and side effects of therapy. Symptom monitoring is a weblink via email or text message with questions asking about symptoms. Hormone therapy for breast cancer can... Read More
Gender:
Female
Ages:
18 years and above
Trial Updated:
11/09/2023
Locations: Tampa General Hospital, Tampa, Florida
Conditions: Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, Hormone Receptor-Positive Breast Carcinoma
A Study to Evaluate the Safety, Tolerability, and Efficacy of MORAb-202 (Herein Referred to as Farletuzumab Ecteribulin), a Folate Receptor Alpha (FRα)-Targeting Antibody-drug Conjugate (ADC) in Participants With Selected Tumor Types
Recruiting
The primary objectives of the study are: (1) in the dose-escalation part: to evaluate safety and tolerability and to determine the recommended Phase 2 dose (RP2D) of farletuzumab ecteribulin (MORAb-202) in participants with selected tumor types (ovarian cancer [OC], endometrial cancer [EC], non-small cell lung carcinoma [NSCLC], triple-negative breast cancer [TNBC]), and (2) in dose-confirmation part: to evaluate preliminary efficacy measured by objective response rate (ORR) of farletuzumab ecte... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
10/30/2023
Locations: H Lee Moffitt Cancer Center and Research Institute, Tampa, Florida
Conditions: Solid Tumor
Safety and Efficacy of ALLO-316 in Subjects With Advanced or Metastatic Clear Cell Renal Cell Carcinoma
Recruiting
This is a Phase 1 dose escalation study following a 3+3 study design. The purpose of the TRAVERSE study is to assess the safety, efficacy, and cell kinetics of ALLO-316 in adults with advanced or metastatic clear cell renal cell carcinoma after a lymphodepletion regimen comprising fludarabine, cyclophosphamide, and ALLO-647 to define a Phase 2 dose.
Gender:
All
Ages:
Between 18 years and 75 years
Trial Updated:
10/30/2023
Locations: Moffitt Cancer Center, Tampa, Florida
Conditions: Advanced/Metastatic Clear Cell Renal Cell Carcinoma